Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.60 |
| ▸ | CA2 | P00918 | 3/20 | 0.60 |
| ▸ | CA7 | P43166 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA4 | P22748 | 1/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.60 |
| ▸ | CTSD | P07339 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3854662 | 0.87 | KMT2A (0.53) | CA1CA2CA7CA9CA12 | |
| SCHEMBL4077898 | 0.87 | SMN1; SMN2 (0.54) | CA1CA2CA7CA9CA12 | |
| SCHEMBL6225170 | 0.87 | CA1 (0.46) | CA1CA2CA7CA9CA12 | |
| SCHEMBL3862642 | 0.87 | KMT2A (0.53) | CA1CA2CA7CA9CA12 | |
| SCHEMBL9101 | 0.86 | RAB9A (0.58) | CA1CA2CA7CA9CA12 | |
| SCHEMBL7952 | 0.86 | RAB9A (0.58) | CA1CA2CA7CA9CA12 | |
| SCHEMBL383152 | 0.84 | POLB (0.51) | CTSDRAB9AHTTSMN1; SMN2MEN1 | |
| SCHEMBL2119268 | 0.82 | CA1 (0.57) | CA1CA2CA7CA9CA12 | |
| SCHEMBL3277622 | 0.82 | CA1 (0.57) | CA1CA2CA7CA9CA12 | |
| SCHEMBL322168 | 0.80 | CTSD (0.62) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1982 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218365-A1 | FORMULATION OF AN ANTISENSE OLIGOMER CONJUGATE | THE PROGERIA RESEARCH FOUNDATION, INC. | 2024-07-04 | — | — | US | claimed |
| EP-4392558-A1 | ANTISENSE OLIGONUCLEOTIDES HAVING ONE OR MORE ABASIC UNITS | Sarepta Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| US-20240209016-A1 | FLUORESCENT NUCLEOSIDE PHOSPHATES | STEALTH LABELS BIOTECH AB (SE) | 2024-06-27 | — | — | US | claimed |
| EP-4387676-A2 | DELIVERY OF ANITSENSE OLIGOMERS BY MIRROR IMAGE PEPTIDES | Sarepta Therapeutics, Inc. (US) | 2024-06-26 | — | — | EP | claimed |
| WO-2024114776-A1 | BICYCLIC ABASIC NUCLEIC ACID ANALOGS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | 上海舶望制药有限公司 | 2024-06-06 | — | — | WO | claimed |
| CN-118019847-A | Antisense oligonucleotides with one or more abasic units | 萨勒普塔医疗公司 | 2024-05-10 | — | — | CN | claimed |
| WO-2024097822-A1 | FORMULATION OF AN ANTISENSE OLIGOMER CONJUGATE | SAREPTA THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | claimed |
| WO-2024064237-A2 | DMD ANTISENSE OLIGONUCLEOTIDE-MEDIATED EXON SKIPPING EFFICIENCY | SAREPTA THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | claimed |
| EP-3464306-B1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | SAREPTA THERAPEUTICS INC (US) | 2024-03-27 | — | — | EP | claimed |
| EP-4323373-A1 | FLUORESCENT NUCLEOSIDE PHOSPHATES | STEALTH LABELS BIOTECH AB (SE) | 2024-02-21 | — | — | EP | claimed |
| US-RE34069-E | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES | BIOSYNTECH GMBH (DE) | 1992-09-15 | — | — | US | claimed |
| EP-0456514-A1 | 2-Fluoroneplanocin A and its production | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1991-11-13 | — | — | EP | claimed |
| EP-0135587-B1 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS | SYNGENE, INC. (US) | 1990-05-02 | — | — | EP | claimed |
| US-4800166-A | TRITYL HALIDE OR CARVOXYLATE TO BIND WITH FREE AMINO GROUPS | APPLIED PROTEIN TECHNOLOGIES, INC. (US) | 1989-01-24 | — | — | US | claimed |
| EP-0152459-B1 | PROCESS FOR PRODUCING OLIGONUCLEOTIDES | BIOSYNTECH Biochemische Synthesetechnik GmbH (DE) | 1988-11-02 | — | — | EP | claimed |
| EP-0267996-A1 | New nucleotide derivatives | TAMIR BIOTECHNOLOGY LTD. (IL) | 1988-05-25 | — | — | EP | claimed |
| US-4725677-A | USING PHOSPHINE DERIVATIVE | BIOSYNTECH GMBH (DE) | 1988-02-16 | — | — | US | claimed |
| EP-0135587-A4 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS. | MOLECULAR BIOSYSTEMS INC (US) | 1986-04-02 | — | — | EP | claimed |
| EP-0135587-A1 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS. | MOLECULAR BIOSYSTEMS INC (US) | 1985-04-03 | — | — | EP | claimed |
| WO-1984003285-A1 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS | MOLECULAR BIOSYSTEMS INC (US) | 1984-08-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209016-A1 | FLUORESCENT NUCLEOSIDE PHOSPHATES | RNGTT, PNP, RNMT | CA1 3658/4885CA2 1979/4885CA7 1462/4885 |
| US-20240218365-A1 | FORMULATION OF AN ANTISENSE OLIGOMER CONJUGATE | POLB, GBA1, POLN | CA1 4821/4885CA2 4807/4885CA7 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.